Anticancer Res

1. TAKASHIMA Y, Yoshii K, Tanaka M, Tashiro K, et al
   Ubiquitin-proteasome Pathway-linked Gene Signatures as Prognostic Indicators in Prostate Cancer.
   Anticancer Res. 2025;45:1825-1841.
   

   >> Share

   
   
2. AOKI M, Matsui H, Kurihara S, Ohtake N, et al
   Comparison of BRCA2 Single Nucleotide Variants Between Japanese Patients With Familial Prostate Cancer, Sporadic Prostate Cancer, and Benign Prostatic Hyperplasia.
   Anticancer Res. 2025;45:2195-2204.
   

   >> Share

   
   

   
   BMC Cancer

3. QIU Y, Wang Y, Liu J, Sun K, et al
   Single-cell sequencing unveils the transcriptomic landscape of castration-resistant prostate cancer-associated fibroblasts and their association with prognosis and immunotherapy response.
   BMC Cancer. 2025;25:813.
   

   >> Share

   
   
4. ZHAI J, Liu S, Wang T, Wang Y, et al
   Prognosis, immunological features and potential mechanisms of HKR1 in prostate cancer via single-cell and bulk RNA-sequencing.
   BMC Cancer. 2025;25:822.
   

   >> Share

   
   
5. WANG J, An H, Tao N
   Association of non-insulin-based insulin resistance indices, mean platelet volume and prostate cancer: a cross-sectional study.
   BMC Cancer. 2025;25:795.
   

   >> Share

   
   
6. HUANG Y, Wei C, Chen F, Zhang Y, et al
   Comparing the biopsy strategies of prostate cancer: a systematic review and network meta-analysis.
   BMC Cancer. 2025;25:786.
   

   >> Share

   
   
7. KITAHAMA K, Shigematsu Y, Sugawara E, Amori M, et al
   Clinicopathological characteristics of transcription factor-defined subtypes in bladder small cell carcinoma.
   BMC Cancer. 2025;25:766.
   

   >> Share

   
   

   
   BMC Urol

8. HAFIANI H, Hafiani I, Hafiani M
   Sarcomatoid prostate carcinoma: a case report.
   BMC Urol. 2025;25:104.
   

   >> Share

   
   

   
   Cancer Res

9. SMELIK M, Diaz-Roncero Gonzalez D, An X, Heer R, et al
   Combining Spatial Transcriptomics, Pseudotime, and Machine Learning Enables Discovery of Biomarkers for Prostate Cancer.
   Cancer Res. 2025 Apr 28. doi: 10.1158/0008-5472.CAN-25-0269.
   

   >> Share

   
   
10. CRUZ-HERNANDEZ CD, Smith B, Billet S, Thiruvalluvan M, et al
    A Cyanobacteria-derived RNA aptamer resensitizes prostate cancer to hormone therapy.
    Cancer Res. 2025 Apr 28. doi: 10.1158/0008-5472.CAN-24-4039.
    

    >> Share

    
    

    
    Clin Cancer Res

11. WERNECK GOMES H, Lister NL, Keerthikumar S, Niranjan B, et al
    p-AKT protein expression predicts response to AKT inhibitor combined with docetaxel therapy in adenocarcinoma and neuroendocrine prostate cancer.
    Clin Cancer Res. 2025 Apr 25. doi: 10.1158/1078-0432.CCR-24-3848.
    

    >> Share

    
    
12. ARAFA AT, Yadav S, Marshall CH, Mauer E, et al
    Germline-Somatic Interactions in BRCA-Associated Cancers: Unique Molecular Profiles and Clinical Outcomes Linking ATM to TP53 Synthetic Essentiality.
    Clin Cancer Res. 2025;31:1730-1745.
    

    >> Share

    
    

    
    Curr Treat Options Oncol

13. GREWAL K, Dorff TB, Mukhida SS, Agarwal N, et al
    Advances in Targeted Therapy for Metastatic Prostate Cancer.
    Curr Treat Options Oncol. 2025 Apr 29. doi: 10.1007/s11864-025-01323.
    

    >> Share

    
    

    
    Eur Radiol

14. AGROTIS G, Pooch EP, Marsitopoulos K, Vlychou M, et al
    Detection rates for prostate cancer using PI-RADS 2.1 upgrading rules in transition zone lesions align with risk assessment categories: a systematic review and meta-analysis.
    Eur Radiol. 2025 Apr 27. doi: 10.1007/s00330-025-11618.
    

    >> Share

    
    
15. CARLETTI F, Maggi M, Fazekas T, Rajwa P, et al
    Diagnostic accuracy of multiparametric MRI for detecting unconventional prostate cancer histology: a systematic review and meta-analysis.
    Eur Radiol. 2025 Apr 30. doi: 10.1007/s00330-025-11603.
    

    >> Share

    
    

    
    Eur Urol

16. NG AB, Giganti F, Kasivisvanathan V
    Artificial Intelligence in Prostate Cancer Diagnosis on Magnetic Resonance Imaging: Time for a New PARADIGM.
    Eur Urol. 2025 Apr 30:S0302-2838(25)00252-0. doi: 10.1016/j.eururo.2025.
    

    >> Share

    
    

    
    Int J Urol

17. ROLDAN-TESTILLANO R, Sanchez-Salas R
    Editorial Comment on "Active Surveillance in Prostate Cancer With Intermediate-Risk Features: The PRIAS-JAPAN Study".
    Int J Urol. 2025 Apr 25. doi: 10.1111/iju.70083.
    

    >> Share

    
    

    
    Invest Radiol

18. SKWIERAWSKA D, Bickelhaupt S, Bachl M, Janka R, et al
    Relevance of Prostatic Fluid on the Apparent Diffusion Coefficient: An Inversion Recovery Diffusion-Weighted Imaging Investigation.
    Invest Radiol. 2025;60:357-368.
    

    >> Share

    
    

    
    J Nucl Med

19. CHEN DC, Buteau JP, Emmett L, Alipour R, et al
    Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate- to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [(68)Ga]Ga-PSMA-11 PET/CT in the proPSMA Study.
    J Nucl Med. 2025 Mar 27:jnumed.124.268901. doi: 10.2967/jnumed.124.268901.
    

    >> Share

    
    
20. HARSINI S, Soleimani M, Wilson D, Uribe C, et al
    A Phase I/II Study of [(177)Lu]Lu-HTK03170 with Personalized Dosimetry in Patients with Metastatic Castration-Resistant Prostate Cancer: Clinical Trial Protocol.
    J Nucl Med. 2025 Apr 30:jnumed.124.269064. doi: 10.2967/jnumed.124.269064.
    

    >> Share

    
    

    
    J Urol

21. FURRER MA, Sathianathen NJ, Mulholland CJ, Papa N, et al
    Pelvic lymph node dissection in prostate cancer - is it really necessary? A multicentric longitudinal study assessing oncological outcomes in prostate cancer patients undergoing pelvic lymph node dissection vs radical prostatectomy only.
    J Urol. 2025 Apr 28:101097JU0000000000004587. doi: 10.1097/JU.0000000000004587.
    

    >> Share

    
    
22. CHAPPIDI MR, Newcomb LF, Zheng Y, Liu M, et al
    Magnetic Resonance Imaging at second surveillance biopsy after diagnosis in patients with Grade Group 1 prostate cancer in the Canary Prostate Active Surveillance Study.
    J Urol. 2025 Apr 30:101097JU0000000000004592. doi: 10.1097/JU.0000000000004592.
    

    >> Share

    
    

    
    Oncogene

23. WALKE P, Price JDW, Vizeacoumar FS, Joseph N, et al
    A novel role for Neurog2 in MYCN driven neuroendocrine plasticity of prostate cancer.
    Oncogene. 2025 Apr 29. doi: 10.1038/s41388-025-03413.
    

    >> Share

    
    

    
    PLoS One

24. JARBUR E, Godtman RA, Bonander C, Stromberg U, et al
    Associations between neighbourhood characteristics and participation in a population-based organised prostate cancer testing (OPT) programme: A register-based study of 50-year-old men.
    PLoS One. 2025;20:e0322643.
    

    >> Share

    
    

    
    Prostate

25. GOUVEIA A, Mesci A, Isfahanian N, Dayes I, et al
    Primary Analysis of (NCT03380806) a Phase II Randomized Trial of Stereotactic Body Radiotherapy Boost Versus Conventional Fractionation External Beam Radiotherapy Boost in Unfavorable-Intermediate and High-Risk Prostate Cancer.
    Prostate. 2025 Apr 27. doi: 10.1002/pros.24905.
    

    >> Share

    
    
26. ASIRI IM, Chen RC, Master V, Mi L, et al
    Thromboembolic Events in Castration-Resistant Prostate Cancer Patients With and Without Cardiovascular Comorbidities Receiving Oral Androgen Receptor Pathway Inhibitors.
    Prostate. 2025 May 1. doi: 10.1002/pros.24902.
    

    >> Share

    
    

    
    Urology

27. ASSANI KD, Scarpato KR
    Editorial Comment on Low baseline IsoPSA Index is associated with a Prolonged Low Risk of Clinically Significant Prostate Cancer Diagnosis in Men with an Elevated PSA.
    Urology. 2025 Apr 29:S0090-4295(25)00402-9. doi: 10.1016/j.urology.2025.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share